Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 11:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 9,138 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
wild-type reovirus
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cancer
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Completed Phase 2 Interventional Results available

RNS® System Feasibility Study

NCT00079781
Conditions
Epilepsy
Interventions
RNS® System implantation, RNS® System responsive stimulation
Procedure · Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Pembrolizumab, Sonidegib
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Prostate Cancer
Interventions
225Ac-PSMA-R2, 68Ga-PSMA-R2, 68Ga-PSMA-11
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Conditions
Tricuspid Valve Regurgitation
Interventions
Edwards FORMA Tricuspid Transcatheter Repair System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 2 more
Conditions
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
907
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more
Conditions
Pulmonary Emphysema
Interventions
Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
Device · Other
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Completed Phase 2Phase 3 Interventional Results available

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rituximab, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
Conditions
Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions
Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
Conditions
Rheumatoid Arthritis
Interventions
MabThera/Rituxan, Methotrexate, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more
Conditions
Breast Cancer
Interventions
ceramide
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
13
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Lung Surgery, Radiation therapy
Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
40
States / cities
La Jolla, California • Aurora, Colorado • Colorado Springs, Colorado + 34 more
Conditions
Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous Gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy

NCT01085513
Conditions
Intestinal Abnormalities
Interventions
PillCam SB2
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
16 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Ischemic Stroke
Interventions
Vagus nerve stimulation (VNS) paired with mobility training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Inclusion Body Myositis
Interventions
ABC008
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more
Conditions
Magnetic Resonance Imaging
Interventions
MRI Scan
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Recruiting No phase listed Observational Accepts healthy volunteers

Late Onset Alzheimer's Disease

NCT05010603
Conditions
Alzheimer Disease
Interventions
Blood Draw, Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Miami, Florida • Aurora, Illinois + 9 more
Conditions
Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
60
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 23 more
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
30
States / cities
Loma Linda, California • Los Angeles, California • Pasadena, California + 24 more